Cancer research, translated for clinical judgment.
ASCO Daily News turns recent oncology research into structured conversations for clinical audiences. Episodes move from trial design and endpoints to treatment selection, toxicity, feasibility, and the questions that remain in practice.
PRESS PLAY
ASCO Daily News is a professional oncology briefing built around expert interviews and recent cancer research. Its center of gravity is clinical decision-making. Rather than flattening studies into headlines, episodes spend time on trial populations, endpoints, toxicity, access, feasibility, and the limits of evidence. The show assumes a medically fluent audience. Recent conversations have covered AI in oncology, high-risk smoldering multiple myeloma, EGFR-mutated non-small cell lung cancer, GU cancer data, head and neck cancer personalization, low-dose immunotherapy, GI cancer abstracts, and ASCO Annual Meeting research previews. The register is collegial and technical. Dr. Monty Powell often frames the conversation from the perspective of a medical oncologist, then brings in disease-focused guests to clarify what matters in the clinic. That structure gives the show a useful tension. New data are treated seriously, but not automatically as simple answers. An episode on AI emphasizes source checking, clinical context, hallucination risk, and the danger of letting convenience outrun judgment. The smoldering myeloma discussion considers daratumumab, fixed-duration treatment, early intervention, and the shift away from a pure watch-and-wait posture for selected high-risk patients. The EGFR-positive lung cancer episode weighs disease biology, patient priorities, and care-delivery feasibility. Symposium-highlight episodes function like curated conference notes, moving quickly through abstracts while still naming the clinical question behind each result. The head and neck cancer discussion follows circulating tumor DNA, HPV-related disease, surveillance, recurrence risk, and de-escalation studies. The low-dose pembrolizumab episode brings cost, toxicity, global access, and triple negative breast cancer into the same frame. The show is careful about boundaries. Its closing disclaimers repeatedly stress education and information rather than diagnosis or individual treatment. That matters because the material can be highly specific and consequential. ASCO Daily News is best for clinicians, researchers, trainees, and oncology-adjacent professionals who want to hear how specialists reason through changing evidence. It rewards listeners who already know the vocabulary. It also captures the texture of oncology as it is practiced now: biomarker-driven, trial-aware, cost-conscious, and full of judgment calls.
Made for: This show is for oncologists, oncology trainees, researchers, advanced practice clinicians, and medically fluent listeners following cancer trials and treatment standards. It suits people who want expert context, not simplified health advice.
What sets it apart: ASCO Daily News stands out by keeping the conversation close to clinical evidence and real-world decision points. Episodes connect conference data, trial design, biomarkers, toxicity, access, and patient priorities without turning research into hype.
The ASCO Daily News Podcast features oncologists discussing the latest research and therapies in their areas of expertise.
An oncology trial sounds settled until Dr. Monty Powell asks what you'd actually change in practice.
Press play if you want
Short reviews from the PlayNext desk, based on the episodes we processed.
A grounded oncology review of AI's speed, source-checking, hallucination risk, and the clinical judgment that still has to lead.
AI in oncology is framed with the stakes kept in view: toxic treatments, clinical decisions, and cases where the margin for error can feel life and death. Dr.
A measured look at how AQUILA is pushing high-risk smoldering myeloma past watchful waiting.
High-risk smoldering multiple myeloma is making watch-and-wait feel less settled. Monty Powell leads Vincent Rajkumar, lead investigator of AQUILA and senior author on the manuscript, and Sadhu Somani through a focused discussion of daratumumab after its FDA approval in this…
A grounded discussion of how clinicians weigh EGFR-positive lung cancer treatment choices against toxicity, logistics, and patient priorities.
Treatment choices in EGFR-positive lung cancer are presented here as a balance between efficacy, toxicity, quality of life, and the practical realities of care. Dr. Monty Powell and Dr.
A focused ASCO GU recap that puts bladder cancer data into clear clinical perspective.
The ASCO Daily News Podcast shapes highlights from the 2026 ASCO GU Cancer Symposium into a clear, data-forward discussion with practical clinical interest. Dr. Monty Powell and Dr.
A clinically focused look at how circulating tumor DNA may guide strategy and surveillance in head and neck cancer.
Personalized treatment in head and neck cancer gets a focused, clinically grounded treatment as Dr. Monty Powell speaks with Dr. Ari Rosenberg about HPV-related disease, circulating tumor DNA, and the molecular signals that may shape care.
Oncology evidence translated into clinical decisions.
Critical care evidence, carefully talked through.
Clinical research, reduced to its practical signal.
ASCO Daily News hosts Dr.
Experts discuss the AQUILA trial and FDA approval of daratumumab for high-risk smoldering multiple myeloma, shifting from watch-and-wait to early treatment.
Dr.
Highlights key abstracts from the 2026 ASCO GU Cancers Symposium, focusing on bladder cancer research and patient-centered care.
ASCO Daily News hosts Dr.
Atul Batra says fewer than 5% of patients in India could access standard-dose pembrolizumab, prompting AIIMS New Delhi to test a lower-dose approach in the PLANET study.
The DISCO trial cut futile surgeries from over 40% to about 20% using diffusion-weighted MRI for peritoneal staging.
Dr.
ASCO Daily News host Dr.
Dr.
Dr.
Dr.
Dr.